TCE2 Stock Overview A biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Celldex Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Celldex Therapeutics Historical stock prices Current Share Price US$24.00 52 Week High US$47.80 52 Week Low US$21.80 Beta 1.59 1 Month Change -6.98% 3 Month Change -25.93% 1 Year Change -33.70% 3 Year Change -31.93% 5 Year Change 1,137.11% Change since IPO -56.52%
Recent News & Updates
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases Nov 20
Founder recently bought €290k worth of stock Nov 15
Third quarter 2024 earnings released: US$0.64 loss per share (vs US$0.81 loss in 3Q 2023) Nov 08
Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab Oct 27
New major risk - Revenue and earnings growth Sep 26
New major risk - Revenue and earnings growth Aug 12 See more updates
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases Nov 20
Founder recently bought €290k worth of stock Nov 15
Third quarter 2024 earnings released: US$0.64 loss per share (vs US$0.81 loss in 3Q 2023) Nov 08
Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab Oct 27
New major risk - Revenue and earnings growth Sep 26
New major risk - Revenue and earnings growth Aug 12
Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.65 loss in 2Q 2023) Aug 09
Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria Jul 30
New minor risk - Share price stability Jul 26
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria Jul 17
Senior VP & Chief Medical Officer recently sold €1.5m worth of stock Jun 13
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024 Jun 05
Senior VP recently sold €314k worth of stock Jun 05
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis May 16
First quarter 2024 earnings released: US$0.56 loss per share (vs US$0.62 loss in 1Q 2023) May 07
Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024 Apr 27
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria Apr 17 Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million. Mar 02
Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million. Mar 01
Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Feb 29
Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024 Feb 27
Full year 2023 earnings released: US$2.92 loss per share (vs US$2.40 loss in FY 2022) Feb 27 Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.
New minor risk - Shareholder dilution Nov 09 Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million. Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering. Nov 08
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria Nov 07
New major risk - Share price stability Nov 06
New major risk - Revenue and earnings growth Nov 04
Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2022) Nov 03
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023 Sep 27
New major risk - Revenue and earnings growth Aug 23
New major risk - Revenue and earnings growth Aug 10
Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.77 loss in 2Q 2022) Aug 09
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Jul 12
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis Jul 07
Now 22% undervalued after recent price drop Jun 17
Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023 Jun 12
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023 Jun 10
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies Jun 01
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 May 16
First quarter 2023 earnings released: US$0.62 loss per share (vs US$0.49 loss in 1Q 2022) May 06
Full year 2022 earnings released: US$2.40 loss per share (vs US$1.65 loss in FY 2021) Mar 02
Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors Feb 17
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chronic Inducible Urticaria At Global Urticaria Forum 2022 Dec 07
Second quarter 2022 earnings released: US$0.77 loss per share (vs US$0.34 loss in 2Q 2021) Aug 09
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria Jul 22
Celldex Therapeutics, Inc. Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022 Jul 01
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Jun 22
Celldex Therapeutics, Inc. Announces Board Appointments Jun 17
First quarter 2022 earnings released: US$0.49 loss per share (vs US$0.42 loss in 1Q 2021) May 07
Insufficient new directors Apr 27
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 02
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis Dec 09
Third quarter 2021 earnings released: US$0.45 loss per share (vs US$0.36 loss in 3Q 2020) Nov 10
Celldex Therapeutics, Inc. Announces Initiation of CDX-0159 Subcutaneous Formulation Study Sep 15
Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.50 loss in 2Q 2020) Aug 08
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial Jun 05
Celldex Therapeutics, Inc. Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021 Jun 02
First quarter 2021 earnings released: US$0.42 loss per share (vs US$0.72 loss in 1Q 2020) May 08
Celldex Provides Reports Impairment for the Fourth Quarter of 2020 Mar 31
Full year 2020 earnings released: US$2.02 loss per share (vs US$3.51 loss in FY 2019) Mar 30
New 90-day high: €24.00 Mar 03
Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN) Feb 23
New 90-day high: €20.00 Feb 05
Celldex Therapeutics, Inc. Promotes Freddy Jimenez, to the Newly Created Position of Senior Vice President and General Counsel Jan 05
Celldex Therapeutics, Inc. Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria Dec 10
New 90-day high: €19.13 Nov 28
Celldex Therapeutics, Inc. Initiates Phase 1B Study of Cdx-0159 in Chronic Spontaneous Urticaria Oct 14
Celldex Therapeutics, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Aug 04 Shareholder Returns TCE2 DE Biotechs DE Market 7D -2.4% -0.8% -1.6% 1Y -33.7% -13.0% 6.8%
See full shareholder returns
Return vs Market: TCE2 underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is TCE2's price volatile compared to industry and market? TCE2 volatility TCE2 Average Weekly Movement 7.5% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: TCE2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TCE2's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.
Show more Celldex Therapeutics, Inc. Fundamentals Summary How do Celldex Therapeutics's earnings and revenue compare to its market cap? TCE2 fundamental statistics Market cap €1.60b Earnings (TTM ) -€148.21m Revenue (TTM ) €9.60m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TCE2 income statement (TTM ) Revenue US$9.98m Cost of Revenue US$147.04m Gross Profit -US$137.06m Other Expenses US$17.02m Earnings -US$154.08m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.32 Gross Margin -1,373.91% Net Profit Margin -1,544.48% Debt/Equity Ratio 0%
How did TCE2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 18:52 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Celldex Therapeutics, Inc. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Wittes Aegis Capital Corporation Jonathan Aschoff Brean Capital Kristen Kluska Cantor Fitzgerald & Co.
Show 18 more analysts 
